Abstract:BackgroundStrimvelis (autologous CD34+ cells transduced to express adenosine deaminase [ADA]) is the first ex vivo stem cell gene therapy approved by the European Medicines Agency (EMA), indicated as a single treatment for patients with ADA-severe combined immunodeficiency (ADA-SCID) who lack a suitable matched related bone marrow donor. Existing primary immunodeficiency registries are tailored to transplantation outcomes and do not capture the breadth of safety and efficacy endpoints required by the EMA for the long-term monitoring of gene therapies. Furthermore, for extended monitoring of Strimvelis, the young age of children treated, small patient numbers, and broad geographic distribution of patients all increase the risk of loss to follow-up before sufficient data have been collected. Establishing individual investigator sites would be impractical and uneconomical owing to the small number of patients from each location receiving Strimvelis.ResultsAn observational registry has been established to monitor the safety and effectiveness of Strimvelis in up to 50 patients over a minimum of 15 years. To address the potential challenges highlighted above, data will be collected by a single investigator site at Ospedale San Raffaele (OSR), Milan, Italy, and entered into the registry via a central electronic platform. Patients/families and the patient’s local physician will also be able to submit healthcare information directly to the registry using a uniquely designed electronic platform. Data entry will be monitored by a Gene Therapy Registry Centre (funded by GlaxoSmithKline) who will ensure that necessary information is collected and flows between OSR, the patient/family and the patient’s local healthcare provider.ConclusionThe Strimvelis registry sets a precedent for the safety monitoring of future gene therapies. A unique, patient-focused design has been implemented to address the challenges of long-term follow-up of patients treated with gene therapy for a rare disease. Strategies to ensure data completeness and patient retention in the registry will help fulfil pharmacovigilance requirements. Collaboration with partners is being sought to expand from a treatment registry into a disease registry. Using practical and cost-efficient approaches, the Strimvelis registry is hoped to encourage further innovation in registry design within orphan drug development.

Lessons from a negative gene therapy trial for Duchenne muscular dystrophy

Practical considerations for delandistrogene moxeparvovec gene therapy in patients with Duchenne muscular dystrophy

Management of Select Adverse Events Following Delandistrogene Moxeparvovec Gene Therapy for Patients With Duchenne Muscular Dystrophy

The FDA approval of delandistrogene moxeparvovec-rokl for Duchenne muscular dystrophy: a critical examination of the evidence and regulatory process

AAV gene therapy for Duchenne Muscular Dystrophy: lessons learned from a phase 3 trial

AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial

Recent developments and industry interest in gene therapy for Duchenne muscular dystrophy

Clinical development on the frontier: gene therapy for duchenne muscular dystrophy

Genetic neuromuscular disorders: living the era of a therapeutic revolution. Part 2: diseases of motor neuron and skeletal muscle

Gene Therapy for Genetic Syndromes: Understanding the Current State to Guide Future Care

476 Non-viral Gene Delivery Platform for Topically Treating Rare Genodermatoses

The Clinical Development of Taldefgrobep Alfa: An Anti-Myostatin Adnectin for the Treatment of Duchenne Muscular Dystrophy

Advances and Challenges in Gene Therapy for Dystrophic Epidermolysis Bullosa: Insights from Therapeutic Strategies and Animal Models

Ataluren improves myelopoiesis and neutrophil chemotaxis by restoring ribosome biogenesis and reducing p53 levels in Shwachman-Diamond syndrome cells

Gene therapy for Duchenne Muscular Dystrophy: assessing the readiness of Italian centres of expertise

Gene therapy in rare diseases: the benefits and challenges of developing a patient-centric registry for Strimvelis in ADA-SCID

Gene therapy with bidridistrogene xeboparvovec for limb-girdle muscular dystrophy type 2E/R4: phase 1/2 trial results

Therapeutic developments for Duchenne muscular dystrophy

Evolving Role of Viltolarsen for Treatment of Duchenne Muscular Dystrophy

Clinical decision making around commercial use of gene and genetic therapies for spinal muscular atrophy

From unique challenges to inspired solutions: how vector engineering makes in vivo gene therapy possible